Global homeostasis improvements in Angus and Morag expressing subtherapeutic circulating FVIII activity. (A) WBCT of Angus and Morag before and after treatment with 1.5 × 10¹³ vg/kg AAV2-cFVIII and 1.75 × 10¹³ vg/kg AAV6-cFVIII, respectively. (B) Thrombelastography (TEG) measuring the clot formation time and the size of fibrin in citrated plasmas collected from Angus and Morag at 62 and 46 weeks after vector infusion, respectively. The negative control (HemA) tracing is from Angus before AAV therapy.